ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 149 filers reported holding ASCENDIS PHARMA A/S in Q1 2020. The put-call ratio across all filers is 0.46 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,312 | +76.6% | 2,844 | +130.3% | 0.00% | – |
| Q4 2022 | $150,831 | -91.6% | 1,235 | -92.9% | 0.00% | -100.0% |
| Q3 2022 | $1,793,000 | +219.0% | 17,365 | +187.3% | 0.00% | +300.0% |
| Q2 2022 | $562,000 | +56100.0% | 6,044 | +54845.5% | 0.00% | – |
| Q2 2021 | $1,000 | -96.7% | 11 | -95.2% | 0.00% | – |
| Q1 2021 | $30,000 | -80.9% | 231 | -75.5% | 0.00% | – |
| Q4 2020 | $157,000 | +145.3% | 941 | +65.4% | 0.00% | -100.0% |
| Q1 2020 | $64,000 | -74.3% | 569 | -68.2% | 0.00% | -50.0% |
| Q4 2019 | $249,000 | +111.0% | 1,788 | +46.2% | 0.00% | +100.0% |
| Q3 2019 | $118,000 | -81.8% | 1,223 | -78.2% | 0.00% | -83.3% |
| Q2 2019 | $647,000 | +670.2% | 5,615 | +317.5% | 0.01% | +500.0% |
| Q4 2018 | $84,000 | +1100.0% | 1,345 | +1272.4% | 0.00% | – |
| Q2 2018 | $7,000 | – | 98 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |